Capital Asset Advisory Services LLC Boosts Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Capital Asset Advisory Services LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 45.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,484 shares of the medical instruments supplier’s stock after buying an additional 462 shares during the period. Capital Asset Advisory Services LLC’s holdings in Becton, Dickinson and Company were worth $365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the company. Indiana Trust & Investment Management CO lifted its stake in shares of Becton, Dickinson and Company by 126.9% in the 1st quarter. Indiana Trust & Investment Management CO now owns 236 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 132 shares during the last quarter. Fifth Third Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company during the first quarter worth about $542,000. Procyon Advisors LLC increased its position in shares of Becton, Dickinson and Company by 14.2% during the first quarter. Procyon Advisors LLC now owns 15,396 shares of the medical instruments supplier’s stock valued at $3,810,000 after acquiring an additional 1,912 shares during the last quarter. Cardinal Capital Management raised its stake in shares of Becton, Dickinson and Company by 11.5% in the 1st quarter. Cardinal Capital Management now owns 26,275 shares of the medical instruments supplier’s stock valued at $6,502,000 after acquiring an additional 2,704 shares during the period. Finally, Franklin Street Advisors Inc. NC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $11,998,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.2 %

BDX traded up $2.77 on Friday, hitting $233.71. 2,100,394 shares of the company were exchanged, compared to its average volume of 1,453,708. The firm has a 50-day moving average price of $234.36 and a two-hundred day moving average price of $237.84. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a twelve month low of $224.00 and a twelve month high of $287.32. The company has a market cap of $67.54 billion, a price-to-earnings ratio of 51.48, a price-to-earnings-growth ratio of 2.03 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.86 earnings per share. On average, equities analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 1.63%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the sale, the executive vice president now owns 14,608 shares of the company’s stock, valued at approximately $3,457,713.60. The disclosure for this sale can be found here. Insiders have sold a total of 8,615 shares of company stock worth $2,033,381 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on BDX. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. Finally, Barclays lifted their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $280.17.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.